[go: up one dir, main page]

AR049656A1 - Derivados de 2-alquil quinazolinona sustituidos como inhibidores de parp - Google Patents

Derivados de 2-alquil quinazolinona sustituidos como inhibidores de parp

Info

Publication number
AR049656A1
AR049656A1 ARP050102688A ARP050102688A AR049656A1 AR 049656 A1 AR049656 A1 AR 049656A1 AR P050102688 A ARP050102688 A AR P050102688A AR P050102688 A ARP050102688 A AR P050102688A AR 049656 A1 AR049656 A1 AR 049656A1
Authority
AR
Argentina
Prior art keywords
radical
hydrogen
formula
alkanediyl
alkyloxy
Prior art date
Application number
ARP050102688A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR049656A1 publication Critical patent/AR049656A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Surgery (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1), sus formas de N-oxido, sales de adicion farmacéuticamente aceptables y formas estereoquímicamente isoméricas, donde: las líneas de puntos representan enlaces opcionales; X es >N-, >CH- o >CR2- donde R2 es aminocarbonilo; o cuando X es >CR2-, entonces R2 tomado junto con L-Z puede formar un radical bivalente de formula: -C(O)-NH-CH2NR10-; donde R10 es fenilo; -N==Y- es -N-C(O)- o -N=CR4-, donde R4 es hidroxi; R1 es hidrogeno, halo, alquiloxi C1-6 o alquilo C1-6; R3 es hidrogeno o alquiloxi C1-6; Z es un radical seleccionado de un resto de grupo de formulas (2) a (12), donde cada R5, R6, R7 y R8 está seleccionado, de manera independiente, a partir de hidrogeno, halo, amino, alquilo C1-6 o alquiloxi C1-6; o R7 y R8 tomados juntos pueden formar un radical bivalente de formulas: -CH2-CR92-O-; -(CH2)3-O-; -O-(CH2)2-O-; -CH=CH-CH=CH-; donde cada R9 está seleccionado de manera independiente a partir de hidrogeno o alquilo C1-6; y L es un radical bivalente seleccionado de -C(O)-, -C(O)-NH-, -C(O)-alcanodiilo C1-6- o -C(O)-O-alcanodiilo C1-6-; o L puede ser un enlace directo cuando X es >CR2- o cuando Z es un radical de formula (12); con la condicion de que cuando X es >CH-, -N==Y- es -N-C(O)-, la segunda línea de puntos no es un enlace, Z es un radical de formula (3) y L es -C(O)-, entonces -alcanodiilo C1-6- no es -CH2-CH2-.
ARP050102688A 2004-06-30 2005-06-29 Derivados de 2-alquil quinazolinona sustituidos como inhibidores de parp AR049656A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04076887 2004-06-30

Publications (1)

Publication Number Publication Date
AR049656A1 true AR049656A1 (es) 2006-08-23

Family

ID=34928320

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050102688A AR049656A1 (es) 2004-06-30 2005-06-29 Derivados de 2-alquil quinazolinona sustituidos como inhibidores de parp
ARP050102690A AR051920A1 (es) 2004-06-30 2005-06-29 Derivados de quinazolinona como inhibidores del parp, un procedimiento de preparacion, composicion farmaceutica y proceso de preparacion de esta

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP050102690A AR051920A1 (es) 2004-06-30 2005-06-29 Derivados de quinazolinona como inhibidores del parp, un procedimiento de preparacion, composicion farmaceutica y proceso de preparacion de esta

Country Status (23)

Country Link
US (5) US8623872B2 (es)
EP (2) EP1763518B1 (es)
JP (2) JP4969443B2 (es)
KR (2) KR101286969B1 (es)
CN (2) CN1980899B (es)
AR (2) AR049656A1 (es)
AT (2) ATE498613T1 (es)
AU (2) AU2005259188B2 (es)
BR (2) BRPI0512797A (es)
CA (2) CA2568835C (es)
DE (1) DE602005026391D1 (es)
EA (2) EA012837B1 (es)
ES (2) ES2380702T3 (es)
IL (2) IL180382A (es)
MX (2) MXPA06014933A (es)
MY (2) MY140572A (es)
NO (2) NO339883B1 (es)
NZ (2) NZ551680A (es)
SG (2) SG154435A1 (es)
TW (2) TWI361689B (es)
UA (2) UA86237C2 (es)
WO (2) WO2006003146A1 (es)
ZA (2) ZA200610772B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054209A1 (en) 2003-11-20 2005-06-16 Janssen Pharmaceutica N.V. 7-phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-­ribose) polymerase inhibitors
AU2004295058B9 (en) 2003-11-20 2011-06-30 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
MXPA06014933A (es) 2004-06-30 2007-02-28 Janssen Pharmaceutica Nv Derivados de 2-alquil quinazolinona sustituidos como inhibidores de poli(adp-ribosa) polimerasa-1.
EA011552B1 (ru) 2004-06-30 2009-04-28 Янссен Фармацевтика Н.В. Производные хиназолиндиона в качестве ингибиторов parp
KR101211950B1 (ko) 2004-06-30 2012-12-13 얀센 파마슈티카 엔.브이. Ｐａｒｐ 저해제로서의 프탈아진 유도체
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
RU2447889C2 (ru) 2005-07-18 2012-04-20 Бипар Сайенсиз, Инк. Способ лечения рака (варианты)
CA2662337A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
CA2662517A1 (en) 2006-09-05 2008-03-13 Jerome Moore Treatment of cancer
EP2109608B1 (en) * 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
EP2134691B1 (en) 2007-03-08 2012-01-25 Janssen Pharmaceutica, N.V. Quinolinone derivatives as parp and tank inhibitors
PL2215075T3 (pl) 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
SG185952A1 (en) 2007-11-12 2012-12-28 Bipar Sciences Inc Treatment of breast cancer with 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
AU2009228945B2 (en) 2008-03-27 2013-05-02 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
ES2529545T3 (es) 2008-03-27 2015-02-23 Janssen Pharmaceutica, N.V. Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerización de tubulina y PARP
WO2010081778A1 (en) 2009-01-17 2010-07-22 Universität Zürich Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
EP2731940B1 (en) 2011-07-13 2015-08-19 Novartis AG 4 - piperidinyl compounds for use as tankyrase inhibitors
US9227982B2 (en) 2011-07-13 2016-01-05 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors
WO2013012723A1 (en) * 2011-07-13 2013-01-24 Novartis Ag Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
MX367614B (es) 2012-01-20 2019-08-28 Del Mar Pharmaceuticals Uso de hexitoles sustituidos que incluyen dianhidrogalactitol y analogos para tratar enfermedad neoplasica y celulas madre de cancer que incluyen glioblastoma multiforme y meduloblastoma.
EP2812323B1 (en) * 2012-02-09 2016-04-06 Merck Patent GmbH Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
IN2015MN00002A (es) 2012-07-09 2015-10-16 Lupin Ltd
AU2013331493A1 (en) 2012-10-16 2015-04-09 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORyt
CA2888485C (en) 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
ME02794B (me) 2012-10-16 2018-01-20 Janssen Pharmaceutica Nv Metilen vezani hinolinil modulatori ror-gama-t
EP2983674A4 (en) 2013-04-08 2017-05-10 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
AU2014293011A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene
JP6423875B2 (ja) * 2013-07-31 2018-11-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ オキソキナゾリニル−ブタンアミド誘導体
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
ES2742843T3 (es) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
SMT202200094T1 (it) 2013-12-24 2022-05-12 Univ Virginia Commonwealth Uso di solfati di colesterolo ossigenati (ocs) per il trattamento dell’insufficienza epatica acuta
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
MA41168A (fr) * 2014-12-17 2017-10-24 Acraf Nouveaux composés antibactériens
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
SI3325623T1 (sl) 2015-07-23 2019-11-29 Inst Curie Uporaba kombinacije molekule DBAIT in inhibitorjev PARP za zdravljenje raka
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
US20190290656A1 (en) 2015-12-30 2019-09-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pt(iv) prodrugs
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
HUE059768T2 (hu) 2016-08-02 2022-12-28 Univ Virginia Commonwealth 5-kolesztén-3,25-diol, 3-szulfátot (25HC3S) vagy annak gyógyszerészetileg elfogadható sóját és legalább egy ciklikus oligoszacharidot tartalmazó készítmények
JP2020500214A (ja) 2016-11-02 2020-01-09 イミュノジェン・インコーポレーテッド 抗体薬物複合体とｐａｒｐ阻害剤との併用治療
EP3562822B1 (en) * 2016-12-30 2021-03-10 Mitobridge, Inc. Poly-adp ribose polymerase (parp) inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
AU2018260094A1 (en) 2017-04-28 2019-11-07 Akribes Biomedical Gmbh A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
WO2019156975A1 (en) 2018-02-07 2019-08-15 Atherosys, Inc. Apparatus and method to guide ultrasound acquisition of the peripheral arteries in the transverse plane
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
PE20211382A1 (es) * 2018-04-30 2021-07-27 Ribon Therapeutics Inc Piridazinonas como inhibidoras de parp7
CN109251198B (zh) * 2018-09-25 2019-08-23 郝维强 一种用于麻醉的药物及其制备方法和用途
CN113330007A (zh) 2018-10-03 2021-08-31 特沙诺有限公司 尼拉帕利游离碱的晶体形式
TW202039002A (zh) * 2018-12-07 2020-11-01 斯坦福大學托管董事會 缺氧標靶組成物及其與一parp抑制劑之組合以及此等的使用方法
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
EP4065099A4 (en) 2019-11-25 2023-11-29 The Research Foundation for The State University of New York COMBINATION THERAPY USING FABP5 INHIBITORS WITH TAXANS FOR THE TREATMENT OF CANCER
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113480536B (zh) * 2021-04-21 2024-02-23 中国人民解放军海军军医大学 螺环哌啶酮类衍生物
CN117229224A (zh) * 2022-06-07 2023-12-15 中国药科大学 喹唑啉-4(3h)-酮类化合物、制法、组合物和应用
CN115778960B (zh) * 2022-08-19 2024-09-20 广州六顺生物科技有限公司 一种杂芳环衍生物在制备治疗或预防恶病质药物中的应用
CN116410184B (zh) * 2023-04-07 2025-05-27 西南大学 喹唑酮烯酮唑类化合物及其制备方法和应用
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer
CN117024357A (zh) * 2023-07-03 2023-11-10 潍坊医学院 一种针对brca突变的选择性抑制剂及其用途

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1006423B (de) 1952-01-18 1957-04-18 Ciba Geigy Verfahren zur Herstellung von Hydrazinophthalazinen
GB732581A (en) 1952-01-18 1955-06-29 Ciba Ltd Manufacture of hydrazine compounds
US3274194A (en) 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
US3919425A (en) 1971-04-09 1975-11-11 Miles Lab Method of producing vasodilation using certain 3-substituted-quinazoline derivatives
BE792206A (es) 1971-12-02 1973-06-01 Byk Gulden Lomberg Chem Fab
US3879393A (en) 1973-06-18 1975-04-22 Miles Lab Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones
FR2436781A1 (fr) 1978-09-19 1980-04-18 Berri Balzac Derives d'amino-3 (1h,3h) quinazolinedione-2,4, leur procede de preparation et leurs applications en therapeutique
US4335127A (en) 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
JPS5976082A (ja) 1982-10-23 1984-04-28 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
JPS60120872A (ja) 1983-12-01 1985-06-28 Kyowa Hakko Kogyo Co Ltd 新規なヘテロ環状化合物及び強心剤
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
JPS60226862A (ja) 1984-03-26 1985-11-12 ジヤンセン・フア−マシユ−チカ・ナ−ムロ−ゼ・フエンノ−トシヤツプ 抗ウイルス活性ピリダジンアミン類
DK623586A (da) 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
US5231184A (en) 1987-11-23 1993-07-27 Janssen Pharmaceutica N.V. Pridazinamine derivatives
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
GB8827822D0 (en) 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
EP0391462A1 (en) 1989-04-05 1990-10-10 Janssen Pharmaceutica N.V. Synergistic compositions containing ketanserin
US5160727A (en) 1990-02-13 1992-11-03 Warner-Lambert Company Tumor cell sensitization method using quinazolinedione derivatives
IE913473A1 (en) 1990-10-15 1992-04-22 Fujisawa Pharmaceutical Co Quinazoline derivatives and their preparation
CA2134077C (en) 1992-04-23 2002-05-21 Thaddeus R. Nieduzak 4-imidomethyl-1-[2'phenyl-2'oxoethyl-]piperidines as serotonin 5ht2-antagonists, their preparation and use in therapy
TW294595B (es) * 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
EP0638567A4 (en) 1993-02-18 1995-05-10 Kyowa Hakko Kogyo Kk ADENOSINE INHIBITORS.
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
TW445263B (en) * 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
JPH107572A (ja) 1996-06-17 1998-01-13 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
SK285631B6 (sk) 1996-09-10 2007-05-03 Dr. Karl Thomae Gmbh Modifikované aminokyseliny, farmaceutický prostriedok s ich obsahom a ich použitie
CA2291630A1 (en) 1997-05-30 1998-12-03 Tetsutaro Niizato Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same
JPH10330377A (ja) 1997-06-02 1998-12-15 Kyowa Hakko Kogyo Co Ltd ピペリジン誘導体
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
AU9002598A (en) 1997-09-16 1999-04-05 Takeda Chemical Industries Ltd. Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
JP2000191659A (ja) 1999-01-04 2000-07-11 Sumitomo Pharmaceut Co Ltd 腫瘍壊死因子産生阻害剤
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
CZ20012716A3 (cs) 1999-01-29 2001-11-14 Abbott Laboratories Diazabicyklické deriváty jako ligandy nikotinového receptoru acetylcholinu
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1332133B1 (en) 2000-10-02 2008-07-09 Janssen Pharmaceutica N.V. Metabotropic glutamate receptor antagonists
ITMI20002358A1 (it) 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
EP1396488A1 (en) * 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
KR100955015B1 (ko) 2001-08-15 2010-04-28 이코스 코포레이션 2ｈ-프탈라진-1-온 및 이것의 사용 방법
JP2005511581A (ja) 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
AUPR975601A0 (en) * 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
AU2003226737B2 (en) 2002-03-29 2008-09-04 Janssen Pharmaceutica N.V. Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
AR043059A1 (es) 2002-11-12 2005-07-13 Bayer Pharmaceuticals Corp Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
US20050075364A1 (en) 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
AU2004295058B9 (en) 2003-11-20 2011-06-30 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
WO2005054209A1 (en) 2003-11-20 2005-06-16 Janssen Pharmaceutica N.V. 7-phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-­ribose) polymerase inhibitors
CN102127056B (zh) 2003-12-03 2013-08-21 Ym生物科学澳大利亚私人有限公司 微管蛋白抑制剂
UA89618C2 (ru) 2003-12-05 2010-02-25 Янссен Фармацевтика Н.В. 6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы
EA010592B1 (ru) 2003-12-10 2008-10-30 Янссен Фармацевтика Н.В. 6-замещённые циклогексилалкил 2-замещённые хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(adp-рибоза)полимеразы
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
DE102004023332A1 (de) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
AU2005249527B2 (en) 2004-06-01 2011-08-04 University Of Virginia Patent Foundation Dual small molecule inhibitors of cancer and angiogenesis
MXPA06014933A (es) 2004-06-30 2007-02-28 Janssen Pharmaceutica Nv Derivados de 2-alquil quinazolinona sustituidos como inhibidores de poli(adp-ribosa) polimerasa-1.
KR101211950B1 (ko) 2004-06-30 2012-12-13 얀센 파마슈티카 엔.브이. Ｐａｒｐ 저해제로서의 프탈아진 유도체
EA011552B1 (ru) 2004-06-30 2009-04-28 Янссен Фармацевтика Н.В. Производные хиназолиндиона в качестве ингибиторов parp
CN101142198B (zh) 2005-02-17 2012-10-31 辛塔制药公司 用于治疗疾病的异*唑坎布雷它斯丁衍生物
ES2545382T3 (es) 2005-04-28 2015-09-10 Mitsubishi Tanabe Pharma Corporation Derivado de cianopiridina y su uso como medicamento
CN101316592A (zh) 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
CA2640678C (en) 2006-02-03 2015-03-31 Bionomics Limited Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
CN101421268B (zh) 2006-02-15 2016-01-06 Abbvie公司 作为有效parp抑制剂的吡唑并喹诺酮
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
EP2134691B1 (en) 2007-03-08 2012-01-25 Janssen Pharmaceutica, N.V. Quinolinone derivatives as parp and tank inhibitors
WO2009002469A1 (en) 2007-06-25 2008-12-31 Amgen Inc. Phthalazine compounds, compositions and methods of use

Also Published As

Publication number Publication date
US7875621B2 (en) 2011-01-25
TWI361689B (en) 2012-04-11
WO2006003146A1 (en) 2006-01-12
EP1771422A1 (en) 2007-04-11
AU2005259192B2 (en) 2011-04-28
KR101184036B1 (ko) 2012-09-18
KR101286969B1 (ko) 2013-07-23
MXPA06014543A (es) 2007-03-23
CA2569826A1 (en) 2006-01-12
CN1976906A (zh) 2007-06-06
SG154435A1 (en) 2009-08-28
HK1105960A1 (en) 2008-02-29
BRPI0512797A (pt) 2008-04-08
NO20070532L (no) 2007-01-29
AU2005259188A1 (en) 2006-01-12
US20110077245A1 (en) 2011-03-31
ZA200610772B (en) 2008-09-25
EA200700188A1 (ru) 2007-06-29
TWI361188B (en) 2012-04-01
BRPI0512790A (pt) 2008-04-08
JP4969443B2 (ja) 2012-07-04
CA2569826C (en) 2013-07-16
EA200700189A1 (ru) 2007-06-29
US8188103B2 (en) 2012-05-29
CA2568835C (en) 2014-05-27
US20170158673A1 (en) 2017-06-08
DE602005026391D1 (de) 2011-03-31
EP1771422B1 (en) 2011-02-16
MY148322A (en) 2013-03-29
ES2361162T3 (es) 2011-06-14
TW200616978A (en) 2006-06-01
CA2568835A1 (en) 2006-01-12
US9522905B2 (en) 2016-12-20
IL180382A0 (en) 2007-06-03
IL180411A0 (en) 2007-06-03
WO2006003150A1 (en) 2006-01-12
MXPA06014933A (es) 2007-02-28
ATE540936T1 (de) 2012-01-15
EP1763518A1 (en) 2007-03-21
NO339883B1 (no) 2017-02-13
UA85593C2 (uk) 2009-02-10
EA012837B1 (ru) 2009-12-30
EP1763518B1 (en) 2012-01-11
IL180411A (en) 2011-12-29
CN1980899B (zh) 2013-07-24
KR20070043968A (ko) 2007-04-26
TW200608977A (en) 2006-03-16
CN1980899A (zh) 2007-06-13
JP2008504350A (ja) 2008-02-14
NO20070555L (no) 2007-01-30
AU2005259192A1 (en) 2006-01-12
AU2005259192C1 (en) 2012-03-01
EA012416B1 (ru) 2009-10-30
NZ551840A (en) 2009-07-31
US10150757B2 (en) 2018-12-11
ATE498613T1 (de) 2011-03-15
US20080176876A1 (en) 2008-07-24
ZA200610775B (en) 2008-03-26
MY140572A (en) 2009-12-31
AR051920A1 (es) 2007-02-21
CN1976906B (zh) 2010-09-01
HK1105631A1 (en) 2008-02-22
JP2008504347A (ja) 2008-02-14
US8623872B2 (en) 2014-01-07
US20140080835A1 (en) 2014-03-20
AU2005259188B2 (en) 2011-03-31
US20080070915A1 (en) 2008-03-20
SG154434A1 (en) 2009-08-28
UA86237C2 (uk) 2009-04-10
KR20070031944A (ko) 2007-03-20
JP4836946B2 (ja) 2011-12-14
NZ551680A (en) 2010-02-26
IL180382A (en) 2011-11-30
ES2380702T3 (es) 2012-05-17

Similar Documents

Publication Publication Date Title
AR049656A1 (es) Derivados de 2-alquil quinazolinona sustituidos como inhibidores de parp
NZ511739A (en) New esters derived from substituted phenyl-cyclohexyl compounds
YU8703A (sh) Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1
AR057810A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
AR045180A1 (es) Derivados 3-amino cromado y 2-amino tetralina y composiciones que contienen a dichos compuestos
DE69309670D1 (de) Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können
MY144718A (en) Viral polymerase inhibitors.
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
EA200602058A1 (ru) Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
TW200617003A (en) Viral polymerase inhibitors
AR070485A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
YU25696A (sh) Postupak dobijanja kombinacije (r)-5-karbamoil-8-fluoro-3- n,n-disupstituisan-amino-3,4-dihloro-2h-1-bezopirana i farmaceutske formulacije koje ih sadrže
BR0313969A (pt) Inibidores de oxitocina
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
AR075287A1 (es) Metodos para sintetizar una feromona de atraccion sexual del gusano de naranja de ombligo
AR029343A1 (es) USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN
TW200512333A (en) Aqueous solutions of fluorescent whitening agents
GR3032308T3 (en) Pyridine- and imidazole-derived agents for cardiovascular diseases